FMP
Liminal BioSciences Inc.
LMNL
NASDAQ
Inactive Equity
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
8.5 USD
0.01 (0.118%)
Historical Prices
From:
To:
About
ceo
Mr. Bruce Pritchard BA, CA, FIOD
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and ch...
CIK
0001351172
ISIN
CA53272L1031
CUSIP
53272L103
Address
440 Armand-Frappier Boulevard
Phone
14507810115
Country
CA
Employee
251
IPO Date
Dec 18, 2009
Financial Statement
Earnings
LMNL Financial Summary
CIK
0001351172
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
53272L103
ISIN
CA53272L1031
Country
CA
Price
8.5
Beta
1.03
Volume Avg.
23.73k
Market Cap
27.62M
Shares
-
52-Week
3.1-8.5
DCF
2.85
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.24
P/B
-
Website
https://www.liminalbiosciences.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest LMNL News
Zacks Investment Research
Jul 13, 2023
Liminal (LMNL) Up 40% on Buyout Offer From Majority Sharehol...
If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
Market Watch
Jul 12, 2023
Liminal BioSciences stock rockets on take-private deal with ...
Liminal BioSciences Inc. LMNL, -1.33% stock is rallying 41.7% in premarket trades on Wednesday after the company said it agreed to go private at a price of $8.50 a share. Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd.
InvestorPlace
Apr 5, 2023
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?
Liminal Biosciences (NASDAQ: LMNL ) stock is taking off on Wednesday as investors react to the biopharmaceutical company getting an unsolicited transaction proposal. According to a press release from the company, Structured Alpha LP is seeking to acquire Liminal Biosciences for $7.50 per share.
Market Watch
Apr 5, 2023
Liminal Biosciences' stock soars 91% after getting takeover ...
Liminal Biosciences Inc.'s stock LMNL, -4.23% soared 91% in premarket trade Wednesday, after the company said it's received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. That company already owns 64% of the outstanding stock and is now bidding for the rest.
Seeking Alpha
Mar 17, 2023
Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transc...
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.
PRNewsWire
Jan 19, 2023
Liminal BioSciences to Present at BIO CEO & Investor Confere...
LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.
Seeking Alpha
Nov 13, 2022
Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.
Seeking Alpha
May 13, 2022
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 20...
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.
